The Roche vs. Cipla decision is now available on the Delhi High Court Website. The decision can be accessed from here. A detailed analysis will follow soon.
Tuesday, 11 September 2012
Friday, 7 September 2012
India Court Rules Against Swiss Drug Maker Roche
Four years back, an injunction plea by Roche against Indian generic drug maker Cipla to prevent Cipla from manufacturing the generic version of Tarceva (Cancer Drug) was rejected by Delhi high court. News has just come in that the Delhi high court has ruled that Cipla's generic drug erlotinib hydrochloride is not infringing the patent held by Roche for Tarceva. The court also ruled that the patent for Tarceva is valid in India.
This ruling comes in just one week before another high profile case where the Supreme court will be hearing a plea by another Swiss giant Novartis over its cancer drug Glivec.
The details of the judgment are awaited.
This ruling comes in just one week before another high profile case where the Supreme court will be hearing a plea by another Swiss giant Novartis over its cancer drug Glivec.
The details of the judgment are awaited.
Subscribe to:
Posts (Atom)